Engineering High-Performance Yeast Chassis for the Beverage, Biofuel, and Biorefinery Industries. Yeast is the foundational biological engine of the fermentation industry. However, translating laboratory success into industrial profitability requires strains that can survive extreme conditions while maintaining peak productivity. CD Biosynsis offers comprehensive Yeast Strain Development and Screening Services, integrating advanced dual-selection systems, single-cell sequencing, and multi-omics characterization. We empower our clients to identify and evolve elite yeast mutants capable of utilizing complex substrates, tolerating high ethanol concentrations, and excelling in large-scale industrial bioprocessing.
Get a Technical QuoteOur platform provides a seamless transition from vast genetic libraries to validated, production-ready industrial strains. We focus on ranking and selecting the most robust candidates for commercial scale-up.
| Service Tier | Technical Strategy | Primary Application | Standard Deliverables |
|---|---|---|---|
| HTP Phenotypic Screening | Single-cell sequencing & micro-assays | Beverage & Flavor optimization | Elite clones + Metabolic profiles |
| Mutant Library Evolution | Dual-selection (Resistance + Yield) | High-titer Bioethanol production | Stabilized mutants + Yield data |
| Molecular Characterization | Comparative Genomics & Omics | Industrial stress tolerance prediction | Multi-omics report + Robust chassis |
| Substrate Screening | High-lipid accumulation profiling | Lignocellulosic Biorefineries | Specialized strains (e.g. Xylose-utilizing) |
1. Library Generation
2. HTP Screening
3. Omics Evaluation
4. Process Validation
Creating large-scale libraries via chemical mutagenesis or CRISPR-mediated diversity generation.
Formal project proposal and Mutual NDA signing.
Applying customized selection pressures, including dual-selection systems or hypoxic fermentation assays.
Filtering for desired industrial traits such as xylose utilization or high lipid production.
Utilizing comparative genomics and transcriptomics to rank the industrial potential of top candidates.
Predicting tolerance to extreme fermentation conditions to reduce trial-and-error costs.
Validating selected strains in bioreactors to ensure genetic stability and metabolic consistency.
Final delivery of optimized strains along with comprehensive performance dossiers and SOPs.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in the field.
To reduce production costs, strains must be engineered for extreme efficiency. Technical benchmarks utilizing single-cell sequencing screened massive libraries to identify variants with reconstructed hexose phosphorylation pathways. These strains demonstrate high-efficiency glucose fermentation under hypoxic conditions, providing a cost-effective beverage manufacturing platform.
(Reference: Screening large yeast libraries for the beverage industry, 2022)
Standard screening often fails to combine high resistance and high yield. Utilizing a dual-selection system targeting both resistance and performance, researchers isolated yeast mutants that produce 15% more ethanol than wild-type strains under industrial conditions, significantly enhancing biofuel competitiveness.
(Reference: Dual-selection system for improved ethanol production, 2021)
Predicting strain performance at scale is a major bottleneck. By applying genomics and transcriptomics characterization, researchers can evaluate the potential of yeast strains to withstand extreme temperatures. This allows enterprises to quickly select robust strains for large-scale production, reducing trial-and-error costs.
(Reference: Molecular characterization for industrial application potential, 2022)
Non-food biomass utilization requires xylose fermentation and high lipid accumulation. High-throughput screening has identified novel species (e.g. Pseudozyma hubeiensis) that efficiently utilize lignocellulosic hydrolysates to produce high-value oils. These catalysts are essential for next-gen sustainable biorefinery applications.
(Reference: Screening of xylose utilizing and high lipid producing yeast, 2022)
Ready to screen for your next elite industrial yeast strain?
Contact Us1. How do you ensure the isolated mutants remain stable at a 100,000L scale?
Stability is a key metric. We subject top-performing mutants to long-term "stress-stability" trials (over 50 generations) and use Whole Genome Sequencing (WGS) to confirm that beneficial mutations are fixed in the genome.
2. Can you develop strains specifically for high-temperature fermentation?
Yes. By using our comparative omics platform, we can identify thermotolerance markers and utilize Adaptive Laboratory Evolution (ALE) to develop yeast strains that thrive in heat-intensive environments typical of large bioreactors.
3. What exactly is a "Dual-Selection System"?
Standard selection often picks strains that grow well but produce poorly. Dual-selection forces the yeast to maintain high growth while simultaneously hitting specific metabolic production targets, ensuring an elite industrial performer.
4. Do you work with non-conventional yeast species?
Absolutely. While S. cerevisiae is our most common host, we have extensive experience screening and engineering non-conventional species like Pichia pastoris, Yarrowia lipolytica, and Pseudozyma for specialized lipids.
5. What is the typical turnaround time for a mutant screening project?
A standard project—from library generation and HTP screening to molecular characterization and validation—typically takes 12 to 16 weeks.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.